MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative report with the FDA on 2018-11-30 for STIMQ PERIPHERAL NERVE STIMULATOR (PNS) SYSTEM FR8A-RCV-A0,FR8A-SPR-B0 S8R-1A US manufactured by Stimwave Technologies Inc..
[129023889]
Stimwave quality has investigated the details surrounding a complaint resulting from a migration reported to stimwave on (b)(4) 2018, by stimwave clinical specialist. Following a successful trial with the stimq peripheral nerve stimulator (scs) system, the patient had a permanent procedure performed on (b)(6) 2018, in which a stimq receiver stimulator (fr8a-rcv-a0) and spare lead (fr8a-spr-b0) was implanted bilaterally next to the superior cluneal nerve in the patient's back to treat the his chronic back pain. While there were no complications during the procedure, the implanting clinician was not comfortable with the anchoring step of the procedure. The clinical specialist reminded the clinician that anchoring mitigates migration, but the implanting clinician was concerned about the potential for infection. Thus, the clinician deviated from the instructions for use and did not anchor the receiver stimulator and spare lead once placed along the nerve. Once the procedure was completed, the clinical specialist programmed the device and the patient reported good pain relief and was discharged the same day. On (b)(6) 2018, the patient met with the clinical specialist and the implanting clinician for a follow-up appointment and stated that he was no longer receiving any pain relief with his device. The implanting clinician used fluoroscopy to visualize the device, and identified that the stimulator had migrated laterally away from the target superior cluneal nerve. The clinical specialist attempted to reprogram the stimulation parameters of the device, but was unsuccessful. The implanting clinician informed the patient and the clinical specialist that she would consult with another clinician at the clinic for next steps and would follow-up with the planned resolution. The patient returned to the clinic on (b)(6) 2018 and met with the consulting clinician and reported that he had a fever and that the device has started eroding through his skin. The consulting clinician was able to trim the exposed portion of the device, dressed the wound, and prescribed antibiotics. On (b)(6) 2018, that patient returned to the clinic and met with the consulting clinician. At this appointment, the patient reported that the device was continuing to erode, thus the consulting clinician explanted the eroding device. The second device was not explanted. The patient stated that he would like to have the second device explanted, and the entire system re-implanted with the clinician who performed his trial, because of the pain relief he experienced with that system (90% pain relief). Neither stimwave nor the clinical specialist has received any further information from clinic regarding the explant and re-implantation of the system. Immediately following notification, stimwave quality and management reviewed the implanting clinician's procedure compared to the receiver instructions for use with the clinical specialist. The clinical specialist states that the implanting clinician did not comply with the product instructions for use with respect to securing the stimulator and anchoring the receiver. Per the clinical specialist, the implanting clinician elected to complete the procedure using on the needle to inject the stimulator to the nerve target, and complete the entire procedure with the smallest possible wound in an effort to avoid infection. However, the procedure for securing the stimulator instructs clinicians to ensure the stimulator is sutured to the tissue (05-0669-2, page 24, k171366), and for fixating the receiver, physicians may need to cut down in order to find a suitable tissue structure for anchoring (05-0669-2, page 26, k171366). It is likely that clinician noncompliance to the implantation procedure caused the stimulator migration, leading to the device erosion through the skin and pain the patient experienced. The source of the issue was not traced back to inadequate documentation of implant procedure, and the device did not fail to meet performance or safety specifications. Stimulator migration is a known adverse event for peripheral nerve stimulators and the stimq pns system and is mitigated as far as possible in the product's risk management file. Stimwave believes that if the implanting clinician would have followed the ifu, securing the stimulator and anchoring the receiver, this kind of adverse event is less likely to occur. The root cause of the complaint is not attributed to device failure, the inability of the device to meet performance or safety specifications, nor nonconformance to physical or functional device specifications. The root cause is attributed to the implanting clinician's noncompliance to migration mitigation steps detailed in the product's ifu. The stimwave product was not the source of the issue. Corrective action is not required to remedy the root cause of the complaint. The device did not fail to meet performance or safety specifications. Stimwave has confirmed that the issue is a known adverse event, mitigated as far as possible, and documented in the stimwave's risk management file. Stimwave was in constant contact with the clinical specialist starting (b)(4) 2018, regarding the complaint and the root cause investigation. Stimwave confirmed that the implant procedure details steps to mitigate migration, and the product did not fail to meet performance and safety specifications. The source of the issue is clinician noncompliance to migration mitigation steps detailed in the product's ifu. Stimwave has informed all parties that the product was not the source of the issue. In compliance with medical device reporting requirements and responsibilities, stimwave quality and its chief medical officer have determined that this issue is considered reportable as erosion of the device through the skin can lead to an injury, and medical or surgical intervention was required to preclude permanent impairment or damage. Stimwave has reported this as an adverse event to the united states food and drug administration (fda) on november 30, 2018.
Patient Sequence No: 1, Text Type: N, H10
[129023890]
On (b)(6) 2018, in which a stimq receiver stimulator (fr8a-rcv-a0) and spare lead (fr8a-spr-b0) was implanted bilaterally next to the superior cluneal nerve in the patient's back to treat the his chronic back pain. While there were no complications during the procedure, the implanting clinician was not comfortable with the anchoring step of the procedure. The clinical specialist reminded the clinician that anchoring mitigates migration, but the implanting clinician was concerned about the potential for infection. Thus, the clinician deviated from the instructions for use and did not anchor the receiver stimulator and spare lead once placed along the nerve. Once the procedure was completed, the clinical specialist programmed the device and the patient reported good pain relief and was discharged the same day. On (b)(6) 2018, the patient met with the clinical specialist and the implanting clinician for a follow-up appointment and stated that he was no longer receiving any pain relief with his device. The implanting clinician used fluoroscopy to visualize the device, and identified that the stimulator had migrated laterally away from the target superior cluneal nerve.
Patient Sequence No: 1, Text Type: D, B5
| Report Number | 3010676138-2018-00018 |
| MDR Report Key | 8120940 |
| Report Source | COMPANY REPRESENTATIVE |
| Date Received | 2018-11-30 |
| Date of Report | 2018-11-30 |
| Date of Event | 2018-11-13 |
| Date Facility Aware | 2018-11-26 |
| Date Mfgr Received | 2018-11-26 |
| Device Manufacturer Date | 2017-08-01 |
| Date Added to Maude | 2018-11-30 |
| Event Key | 0 |
| Report Source Code | Manufacturer report |
| Manufacturer Link | Y |
| Number of Patients in Event | 0 |
| Adverse Event Flag | 3 |
| Product Problem Flag | 3 |
| Reprocessed and Reused Flag | 3 |
| Reporter Occupation | BIOMEDICAL ENGINEER |
| Health Professional | 3 |
| Initial Report to FDA | 3 |
| Report to FDA | 3 |
| Event Location | 3 |
| Manufacturer Contact | MRS. ELIZABETH GREENE |
| Manufacturer Street | 1310 PARK CENTRAL BOULEVARD S. |
| Manufacturer City | POMPANO BEACH FL 33064 |
| Manufacturer Country | US |
| Manufacturer Postal | 33064 |
| Manufacturer Phone | 8009655134 |
| Manufacturer G1 | STIMWAVE TECHNOLOGIES INC. |
| Manufacturer Street | 1310 PARK CENTRAL BOULEVARD S. |
| Manufacturer City | POMPANO BEACH FL 33064 |
| Manufacturer Country | US |
| Manufacturer Postal Code | 33064 |
| Single Use | 3 |
| Previous Use Code | 3 |
| Event Type | 3 |
| Type of Report | 3 |
| Brand Name | STIMQ PERIPHERAL NERVE STIMULATOR (PNS) SYSTEM |
| Generic Name | PERIPHERAL NERVE STIMULATOR |
| Product Code | GZF |
| Date Received | 2018-11-30 |
| Model Number | FR8A-RCV-A0,FR8A-SPR-B0 |
| Catalog Number | S8R-1A US |
| Lot Number | SWO170828,SWO170828 |
| Device Expiration Date | 2019-08-01 |
| Operator | LAY USER/PATIENT |
| Device Availability | N |
| Device Age | 15 MO |
| Device Eval'ed by Mfgr | R |
| Device Sequence No | 1 |
| Device Event Key | 0 |
| Manufacturer | STIMWAVE TECHNOLOGIES INC. |
| Manufacturer Address | 1310 PARK CENTRAL BOULEVARD S. POMPANO BEACH FL 33064 US 33064 |
| Patient Number | Treatment | Outcome | Date |
|---|---|---|---|
| 1 | 0 | 1. Required No Informationntervention | 2018-11-30 |